Sanofi

A very good morning. The ground-breaking of Sanofi's Evolutive Vaccines Facility comes at an opportune time. In the past two years, the COVID 19 pandemic has ...

This will create a virtuous circle that will strengthen the vibrancy and scale of the industry. For example, the BMAC worked with our institutes of higher learning to ensure that training is industry relevant. Participants were able to learn more about the sector via virtual plant tours and sharing by industry professionals. We have stayed the course and sustained our investments in R&D for the past thirty years. The Biopharmaceutical Manufacturers’ Advisory Council has also been very active in the nurturing of talent. The evolutive characteristics of this facility are necessary, as new manufacturing technologies and product types – such as mRNA – come online. We need to look no further than where we are today – Tuas Biomedical Park. The 280-hectare Tuas Biomedical Park is home to 13 global biopharmaceutical companies and 7,000 workers. Manufacturing output tripled in the past two decades and is now at more than $18billion per year. But we know that vaccines will remain at the heart of how we deal with the threats of infectious diseases. Sanofi’s EVF is the latest addition to Singapore’s biopharma ecosystem. But the EVF will be designed around several fully digitalised modules that allow production of three to four vaccines simultaneously. COVID-19 has reinforced the importance of pandemic preparedness and supply chain resilience.